MM and AML cells with dominant MCL-1 dependency or heterogenous dependency on multiple members—BCL-2, MCL-1, BCL-xL—were predicted to be resistant to BCL-2 inhibitor monotherapy, unless the other members are able to be abrogated [76]. Here, MCL1 is linked to acute myeloid leukemia.